Insulin Family intermediate
Insulin Biosimilars: Peptide Family Reference
Follow-on biologic insulin products demonstrating comparable safety, purity, and efficacy to reference insulin products.
By Encyclopeptide Editorial | 1 min read
insulin biosimilar follow-on generic diabetes
Overview
Insulin biosimilars are follow-on biologic products demonstrating high similarity to an approved reference insulin product through extensive analytical, functional, and clinical comparability studies.
Approved Biosimilars
| Biosimilar | Reference Product | Manufacturer |
|---|---|---|
| Admelog | Humalog | Sanofi |
| Lusduna | Lantus | Merck |
| Semglee | Lantus | Biocon/Viatris |
| Rezvoglar | Lantus | Eli Lilly |
Clinical Impact
Biosimilar competition is expected to reduce insulin costs by 30-50%, improving access for the estimated 500+ million people with diabetes globally.
Chemical Identity
| Property | Value |
|---|---|
| Name | Insulin Biosimilars |
| Category | Insulin Family |
References
- Encyclopeptide Database. “Insulin Biosimilars” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Insulin Biosimilars: Peptide Family Reference with interactive quizzes on Wikipept.
Take a Quiz on Wikipept